Production (Stage)
D
Telomir Pharmaceuticals, Inc. TELO
$2.10 -$0.10-4.55% NASDAQ
Recommendation
Prev Close
$2.10
Volume
109,322
Avg Vol (90D)
150,435
Market Cap
$62.50M
Dividend & Yield
--
52-Week Range
$1.98 - $8.40
P/E (TTM)
--
EPS (TTM)
-$0.4221
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No ...
5/22/2025 - GuruFocus
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No ...
5/21/2025 - GuruFocus
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No ...
5/21/2025 - GuruFocus
Telomir Pharmaceuticals announces $3M in equity financing
5/21/2025 - The Fly
Telomir Pharmaceuticals secures $3M in straight equity sale
5/21/2025 - Seeking Alpha - Healthcare
Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND
5/21/2025 - Accesswire
EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND
5/21/2025 - Benzinga
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following ...
5/15/2025 - GuruFocus
Telomir Pharmaceuticals identifies Telomir-Ag2 as novel drug candidate
5/15/2025 - The Fly
Telomir Pharmaceuticals Unveils Promising Antimicrobial Drug Candidate
5/15/2025 - TipRanks Financial Blog
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
5/15/2025 - Accesswire
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in ...
5/7/2025 - GuruFocus
Telomir Pharmaceuticals (TELO) Reveals Promising Preclinical Data on Telomir-1 TELO Stock News
5/7/2025 - GuruFocus
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in ...
5/7/2025 - GuruFocus
Telomir Pharmaceuticals announces new preclinical data on Telomir-1
5/7/2025 - The Fly
Telomir Pharmaceuticals (TELO) Projected to Post Earnings on Monday
5/7/2025 - MarketBeat
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
5/7/2025 - Accesswire
Geode Capital Management LLC Has $1.71 Million Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)
5/2/2025 - MarketBeat
Surprising Analyst 12-Month Target For IWN
4/16/2025 - ETF Channel
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal ...
3/19/2025 - GuruFocus
Telomir Pharmaceuticals announces preclinical findings on Telomir-1
3/19/2025 - The Fly
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
3/19/2025 - Accesswire
Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model
3/19/2025 - SeekingAlpha.com: All News
Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model
3/19/2025 - Seeking Alpha - Healthcare
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
3/19/2025 - Benzinga
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$12.57M
Net Income (TTM)
-$12.52M
Balance Sheet
Total Assets (Q)
$491.20K
Total Debt (Q)
$93.40K
Total Liabilities (Q)
$652.30K
Book Value Per Share (Q)
-$0.0054
Cash Flow
Cash from Operations (TTM)
-$3.99M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$1.12M
Net Change in Cash (TTM)
-$2.87M
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-11.02%
30-Day Total Return
-21.93%
60-Day Total Return
-47.50%
90-Day Total Return
-56.61%
Year to Date Total Return
-48.40%
1-Year Total Return
-68.84%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
May 22, 2025 - $1.98
52-week High
Sep 20, 2024 - $8.40
Valuation
Market Cap
$62.50M - Micro Cap
Enterprise Value
$62.19M
Price/Sales (TTM)
--
Price/Book (Q)
-388.89
Dividends and Shares
Shares Outstanding
29.76M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
telomirpharma.com
Phone Number
786 396 6723
Address
100 SE 2nd Street
Miami, FL 33131
Country
United States
Year Founded
2021
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Telomir Pharmaceuticals, Inc., a pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed